Type: Press Releases

High Efficiency CAR Discovery Screening

Alloy Therapeutics utilizes a high-efficiency CAR discovery and screening workflow that integrates the ATX-Gx™ humanized mouse platform with rapid cell-based functional assays to accelerate the identification of potent Chimeric Antigen Receptor (CAR) candidates. This streamlined approach enables researchers to optimize binder selection and validate CAR-T efficacy early in the drug development process to reduce timelines […]

Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners

Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities. Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners. BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, […]

Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine

AntiClastic™ is a proprietary antisense oligonucleotide (ASO) platform developed by Alloy Therapeutics, designed to improve the potency and therapeutic index of antisense therapeutics targeting RNA. By combining improvements in primary sequence with novel spatial conformations of nucleic acids, the platform aims to enhance potency, reduce unintended interactions and inflammatory responses, and expand therapeutic opportunities for […]

Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents

Kent Bondensgaard and John Lippincott joined Alloy Therapeutics as key strategic leaders to support the company’s mission of democratizing access to foundational drug discovery technologies. Their combined expertise in corporate development and clinical strategy enhances Alloy’s ability to scale its platform services and foster long-term partnerships with biotechnology and pharmaceutical innovators. Alloy Antibody Discovery Services […]

Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines

The Alloy Therapeutics 2023 Innovation Roadmap outlines the company’s strategic expansion of its drug discovery ecosystem, prioritizing the integration of new modality-agnostic platforms and AI-driven capabilities to accelerate the development of complex biologics. This roadmap serves as a technical guide for partners to navigate the evolving suite of transgenic mouse models, high-throughput screening technologies, and […]

Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology

Normunity is a biotechnology company developing precision immuno-oncology therapies known as immune normalizers, designed to target novel mechanisms of immune disruption and restore the body’s natural ability to fight cancer. Through a multi-program collaboration with Alloy Therapeutics, Normunity leverages Alloy’s high-velocity, sequencing-first antibody discovery technologies to identify therapeutic antibodies against novel immuno-oncology targets, including mechanisms […]

Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities

Alloy Therapeutics secured $42 million in Series D financing to continue the expansion of its democratized ecosystem, which provides drug developers with open access to foundational antibody discovery platforms and services. This funding supports the company’s commitment to scaling its technology infrastructure, enabling scientific partners to advance biotherapeutic pipelines from discovery to the clinic. — […]

Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS

—Trier will lead operations and strategy of people-focused venture studio, supporting ecosystem of scientific entrepreneurs— BOSTON, MA; September 07, 2022–Alloy Therapeutics, a biotechnology ecosystem company, welcomes Trier Bryant as President of 82VS, Alloy’s affiliated venture studio. Trier is a strategic executive leader with distinctive tech, Wall Street, and military experience spanning 15 years, and brings a […]

Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines

Alloy Therapeutics’ intracellular genetic medicines platform provides drug developers with non-exclusive access to novel RNA-based chemistries and discovery technologies designed to target previously undruggable intracellular disease-associated RNAs. This ecosystem expands antibody discovery capabilities into antisense and immunomodulatory modalities to address complex therapeutic targets beyond the cell surface. –Through a partnership with antisense pioneer Agrawal’s Arnay […]

Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning

Alloy Therapeutics led a $7 million Series A for Mytide Therapeutics to scale its AI-enabled Gen2 platform, which uses machine learning to accelerate peptide manufacturing by 30x. This technology enables the rapid, high-purity production of complex natural and non-natural peptides for therapeutic discovery and personalized peptide vaccines (PPV). Biotech ecosystem company Alloy Therapeutics leads the […]